---
schema_version: "secwatch.filing_event.v1"
accession: "0001576885-23-000047"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T01:56:37.642200+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Acumen reports positive Phase 1 results for ACU193; Q2 net loss $11.6M, cash $172.2M + $122M offering

## Summary
- Phase 1 INTERCEPT-AD trial met primary/secondary objectives; ACU193 showed 25% amyloid plaque reduction at 60 mg/kg (p=0.01).
- ACU193 demonstrated near-maximal target engagement of toxic AβOs; low ARIA-E rate of 10.4%, symptomatic 2.1%; no drug-related SAEs.
- Cash, equivalents & securities $172.2M at June 30; July follow-on offering added ~$122M net; runway into H2 2026.
- Phase 2 study initiation expected H1 2024; FDA interaction anticipated Q4 2023 to inform development path.
- Q2 2023 net loss $11.6M vs $10.2M YoY; R&D expenses $9.1M (up from $7.3M); no revenue.

## SEC filing metadata
- accession: 0001576885-23-000047
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000047/0001576885-23-000047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000047/abos-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576885-23-000047
- JSON: https://secwatch.observer/filing/0001576885-23-000047.json
- Plain text: https://secwatch.observer/filing/0001576885-23-000047.txt

## Key facts
- Earnings Releases
  Acumen Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $11.6 million for the three-month period ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Net income: Net loss was $11.6 million for the three-month period ended June 30, 2023
  - Result: reported results
  source text: Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576885/000157688523000047/0001576885-23-000047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.